Curriculum Vitae

Lauren Freidus Katz, M.D.

Education:
1974-78 B.A. Brandeis University
1978-82 M.D. Hahnemann University

Post Graduate Training:
1982-03  Intern in Psychiatry, Hahnemann University Hospital, Philadelphia
1983-86  Resident in Psychiatry, Institute of Pennsylvania Hospital, Philadelphia

Additional Training:
1986-96 Candidate, Institute of the Philadelphia Association for Psychoanalysis, Bala Cynwyd, PA
1985-86 Elective in Child Psychiatry Hahnemann University, Philadelphia

Academic Appointments:
2001- Associate Faculty, Psychoanalytic Center of Philadelphia
2000-01 Adjunct Faculty, Widener University, Institute for Graduate Clinical Psychology
1998-01 Associate Faculty, Institute of the Philadelphia Association for Psychoanalysis
1997- Core Faculty, MCP Hahnemann University, Creative Arts in Therapy Program
1992- Volunteer Faculty, Widener University, Institute for Graduate Clinical Psychology
1983-86 Assistant Instructor in the Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia
1985-86 Visiting Assistant Instructor in the Department of Mental Health Sciences, Hahnemann University, Philadelphia

Administrative Appointments:
2000-01 Admissions Committee, Institute of the Philadelphia Association for Psychoanalysis
1986-89 Quality Assurance Committee, Institute of Pennsylvania Hospital
1985-86 Vice President, Resident's Association, Institute of Pennsylvania Hospital
1984-86 Library Committee, Institute of Pennsylvania Hospital
1983-84 Affective Disorders Committee, Institute of Pennsylvania Hospital

Additional Work Experience:
2005- Consultant to Suburban Research Associates
1989-95 Psychiatric Consultant to Widener University Student Health Services
1988- Private Practice Swarthmore, PA
1986-89 Private Practice Institute of Pennsylvania Hospital, Philadelphia
1986-88 Psychiatric Consultant to TRIS Partial Care Program, Cherry Hill, NJ
1986 Psychiatric Consultant to Hall-Mercer CMHC, Philadelphia
1985-86 Psychiatric Consultant to Horizon House, Philadelphia
1984-86 House Officer, The Fairmount Institute, Philadelphia
1984 Coverage for the Phoenix Detoxification Unit, Oxford Hospital, Philadelphia

Licensure:
MD-030108-E (Pennsylvania)
MA-48054 (New Jersey)

Board Certification:
1988 General Psychiatry

Membership in Professional Societies:
American Psychiatric Association
American Psychoanalytic Association
Pennsylvania Psychiatric Physicians
Psychoanalytic Center of Philadelphia

Clinical Trial Experience

Major Depression

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Aripiprazole as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder. Sponsor- Bristol-Myers Squibb, 2006 (Phase III).

• A Multicenter, Double-Blind, Randomized-withdrawal, Parallel-group Placebo-controlled Phase III Study of the  Efficacy and Safety of Quetiapine Fumarate Sustained Release as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period. Sponsor: Astra Zeneca, 2006 (Phase III).

• Fixed Dose Comparison of Escitalopram to Active comparator in Moderately-to Severely Depressed Patients.  Sponsor: Forest, 2006.

• An eight week, multicenter, randomized, double-blind, placebo and paroxetine-congrooled study of the efficacy, safety and tolerability of agomelatine 25-50 mg given once daily in the treatment of MDD. Sponsor: Novartis, 2007

Attention Deficit Hyperactivity Disorder:

• A Double-Blind Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults with ADHD and Co morbid Social Anxiety Disorder. Sponsor: Eli Lilly, 2006

• A Randomized, Double-Blind Comparison of Placebo and Atomoxetine HCI Given Once a Day in Adults with ADHD: with a Secondary Examination of Impact of Treatment on Family Functioning. Sponsor Eli Lilly, 2006

Bipolar Disorder

• Efficacy of Aripiprazole in Combination with Valproate or Lithium in the Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy. Sponsor: Bristol-Myers Squibb, 2006.

• Safety and Maintenance of effect of Ziprasidone plus mood stabilizer in subjects with Bipolar I disorder. Sponsor: Pfizer, 2007

• A Double Blind Placebo Controlled Trial of Divalproate and Olanzapine in Bipolar I Disorder, Mixed Episode. Sponsor: Eli Lilly, 2007

Generalized Anxiety Disorder

• A Phase 2 Randomized, Double-Blind, Placebo Controlled, Parallel Group, 5 Week Trial to Assess the Efficacy and Safety of PD 0332334 Compared to Placebo and Alprazolam Extended-Release in Patients with Generalized Anxiety Disorder. Sponsor: Pfizer,  2006 (Phase II).

• An Eight-Week, Multicenter, Randomized, Double-blind, Placebo Controlled Study, with Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of Saredutant 100mg Dose Once Daily, in Patients with Generalized Anxiety Disorder. Sponsor: Sanofi Aventis 2006 (Phase II)

Insomnia

•    A Comparison of Zolpidem MR vs. Placebo in the Treatment of Insomnia Associated with Newly Diagnosed Major Depressive Disorder (MDD) or Untreated MDD Relapse when used Concomitantly with Escitalopram. Sponsor: Sanof-Aventis, 2006 (Phase III)

•    A Comparison of Zolpidem MR vs. Placebo in the Treatment of Insomnia Associated with Generalized Anxiety Disorder (GAD) when used Concomitantly with Escitalopram. Sponsor: Sanof-Aventis, 2006 (Phase III)

Schizophrenia

• A multicenter, open label, flexible-dose, parallel-group evaluation of the cataractogenic potential of quetiapine fumarate and risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder. Sponsor: Astra Zeneca, 2005.

• A Randomized, Open-Label Study Comparing the Effects of Olanzapime Pamoate Depot with Oral Olanzapine on Treatment Outcomes in Outpatients with Schizophrenia.  Sponsor: Eli Lilly 2006 (Phase III).

• A Multicenter, Randomized, Double-Blind, Placebo Controlled, 16-Week Study of Aripiprazole Used as Dual therapy in the Treatment of Patients with Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating and Inadequate Response to Quetiapine or Risperidone Monthotherapy. Sponsor: Bristol-Myers Squibb Company, 2006.

Social Anxiety Disorder

• A Randomized, Double Blind Comparison of XXXXX, Paroxetine, and Placebo in the treatment of SAD. Sponsor: Eli Lilly, 2005 (Phase II).

• A Randomized Double Blind Comparison of XXXX, Paroxetine and Placebo in the treatment of SAD. Sponsor: Glaxo Smith Kline, 2007 (Phase II).